vasopressin antagonists

vasopressin antagonists

Non-peptide drugs such as conivaptan and tolvaptan that act by antagonizing the vasopressin receptors in the renal tubules. They are used to treat hyponatraemia in heart failure and liver cirrhosis.
References in periodicals archive ?
Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects in isolated myometrium from preterm and term pregnant women.
Key agents in development are primarily focused on targeting cardiovascular neurohormonal pathways, such as arginine vasopressin antagonists (which include Otsuka's Tolvaptan) and renin-angiotensin aldosterone system modulators (which include Novartis's Aliskiren).
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Renal microvascular effects of vasopressin and vasopressin antagonists.
Turning to the vasopressin antagonists, Mihai Gheorghiade, M.
Three investigational vasopressin antagonists are being developed for patients with both heart failure and hyponatremia.
Two vasopressin antagonists, or "vaptans," have been tested in clinical trials: conivaptan and tolvaptan.